Loading
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Regular session
$9.02
−$0.47 · -4.95%
Regular session · ET · Market data may be delayed.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Day range
Current $9.02
52-week range
Current $9.02
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
71
Bullish
Risk
39
Moderate Risk
Momentum
79
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Day range
Current $9.02
52-week range
Current $9.02
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 16.26M USD | 11.29M USD | 8.74M USD | 4.2M USD | 126.53K USD |
| Selling, general, and administrative | 13.7M USD | 11.38M USD | 7.41M USD | 4.02M USD | 1.23M USD |
| Operating expenses | 29.96M USD | 22.67M USD | 16.14M USD | 8.22M USD | 1.35M USD |
| Interest income | 555.53K USD | 1.02M USD | 572.01K USD | — | — |
| Interest expense | — | — | — | 497 USD | 179.85K USD |
| Depreciation and amortization | 364.5K USD | 115.39K USD | 5.47K USD | 2.14K USD | 2.47K USD |
| Operating income | −29.96M USD | −22.67M USD | −16.14M USD | −8.22M USD | −1.35M USD |
| Net income | −29.44M USD | −21.61M USD | −15.43M USD | −8.23M USD | −24.38M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$23.33
158.65% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI24.98M0.00%2.3T USD0.03%$379.37-0.44%
State Street SPDR S&P Biotech ETFXBI20.78M0.20%10.08B USD0.35%$146.31-2.61%
iShares Russell 2000 ETFIWM14.86M0.02%78.56B USD0.19%$274.61-1.11%
Vanguard Extended Market ETFVXF9.67M0.01%95.4B USD0.05%$231.14-1.01%
iShares Russell 2000 Growth ETFIWO5.28M0.04%14.25B USD0.24%$350.11-1.48%
Vanguard Russell 2000 ETFVTWO3.31M0.02%18B USD0.06%$110.89-1.18%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS2.48M0.62%402.02M USD0.60%$104.73-1.06%
iShares Micro-Cap ETFIWC1.79M0.14%1.33B USD0.60%$180.61-1.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
